Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
EXACT Therapeutics AS ( (DE:56F) ) has shared an update.
EXACT Therapeutics will present new clinical data from its ongoing Phase 2 ENACT trial in locally advanced pancreatic cancer at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco. The study, conducted in collaboration with HonorHealth Research Institute in Arizona, is evaluating the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX, highlighting the company’s efforts to validate its ultrasound-activated PS101 platform in a challenging cancer indication and potentially strengthen its position in the oncology precision medicine landscape.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that uses ultrasound to activate its proprietary drug PS101 and boost the effectiveness of cancer treatments. The company’s platform is designed to be combined with a wide range of oncology agents and potentially extended to other indications such as brain diseases, and its shares are listed on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 50,220
Current Market Cap: NOK94.9M
For detailed information about 56F stock, go to TipRanks’ Stock Analysis page.